Journal
ADVANCES IN CHRONIC KIDNEY DISEASE
Volume 17, Issue 1, Pages 59-71Publisher
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1053/j.ackd.2009.08.013
Keywords
Antiretroviral therapy; HIV-associated nephropathy; Angiotensin-converting enzyme inhibitors; Prednisone; CKD
Categories
Funding
- NIH [AI36219, AI25879]
- NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000080] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI025879, P30AI036219] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Antiretroviral therapy (ART) preserves kidney function in patients with human immunodeficiency virus (HIV)-associated nephropathy (HIVAN). Emerging data also document substantial renal benefits of ART in the general HIV-infected population, which is associated in part with suppression of HIV-1 viral replication. The extent to which the response to ART differs in persons with HIVAN compared with those with other HIV-associated kidney disorders is unknown. Beneficial effects of corticosteroids and angiotensin-converting enzyme inhibitors on kidney function also are suggested by retrospective cohort studies and uncontrolled trials of patients with HIVAN. Underexposure to ART or inadequate ART dosing in HIV-infected patients with CKD may curtail the optimal benefits that may be derived from this therapy. (C) 2010 by the National Kidney Foundation, Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available